Boehringer Ingelheim

(IN BRIEF) Boehringer Ingelheim has launched EURICAN® L4, a new vaccine designed to protect dogs from leptospirosis, a potentially fatal disease spread through contaminated soil and water. Available in France and expanding across Europe in 2025, the vaccine targets four … Read the full press release →

(IN BRIEF) Boehringer Ingelheim has launched VETMEDIN® Solution, the first FDA-approved liquid treatment for congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The solution provides a convenient, twice-daily alternative to tablets, … Read the full press release →

(IN BRIEF) Boehringer Ingelheim and the WHO Foundation have partnered to promote equitable healthcare access and suicide prevention, with a focus on vulnerable communities in the Americas. Boehringer Ingelheim pledged $5 million to support WHO’s 2025–2028 General Program of Work … Read the full press release →

(IN BRIEF) Boehringer Ingelheim and CDR-Life have reported positive results from the Phase I trial of BI 771716, an investigational treatment for geographic atrophy (GA), a severe form of age-related macular degeneration. The antibody fragment met its primary safety endpoints, … Read the full press release →

(IN BRIEF) In a significant stride towards combating metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim unveils groundbreaking results from a Phase II trial sub-analysis of survodutide. Demonstrating impressive efficacy, up to 64.5% of adults with moderate to advanced fibrosis stages F2 … Read the full press release →

(IN BRIEF) A recent study commissioned by Boehringer Ingelheim, conducted across eight G20 countries, sheds light on the challenges obstructing access to mental health care worldwide. The analysis reveals pervasive stigma, a shortage of mental health professionals, and inconsistent service … Read the full press release →

(IN BRIEF) Boehringer Ingelheim and OSE Immunotherapeutics announce a significant expansion of their partnership, introducing two novel projects to develop pioneering treatments alongside their ongoing anti-SIRPα immuno-oncology initiatives. The expansion includes broadening therapeutic evaluations to encompass cardiovascular-renal-metabolic (CRM) diseases and … Read the full press release →

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release →

(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release →

(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release →

(IN BRIEF) Boehringer Ingelheim has been honored by the Top Employers Institute with a “Global Top Employer” certification for the fourth consecutive year, distinguishing it as one of only 17 globally certified companies. The recognition is attributed to the company’s … Read the full press release →